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Description
[0001] The present invention relates to a process for preparing reprogrammed cells, in particular for preparing pluripo-
tent and multipotent stem cells and to the pluripotent and multipotent stem cells prepared by said processes.
[0002] Aging - whether in vivo during the life course or in vitro during scale up - affects cells, in particular stem cells.
For example, aged cells show increased apoptosis rates, decreased differentiation and proliferation capacity, and de-
creased therapeutic effectiveness. During aging, stem cells often differentiate into a less pliable, less proliferative form.
Cell aging represents a problem in particular when using cells from elderly patients/donors as starting material for cell
cultures, when expanding cells in vitro and when using cells that have a limited differentiation capacity for therapy or
research.
[0003] One approach to dedifferentiate aged cells is to create so called Induced Pluripotent Stem Cells (IPS). The
current state of the art foresees to use a viral transfer of transcription factors to induce increased differentiation potency
in cells and to rejuvenate them. This, however, is potentially dangerous because a viral transfer permanently changes
the genome of the cell and also might lead to complications because of the viral parts left behind in the cell genome.
Moreover, viral integration into the genome is known to increase cancer risk in cells. Essentially the same applies to the
use of plasmids for reprogramming cells (Okita et al., 2008, Science. 2008 Nov 7;322(5903):949-53. Generation of
mouse induced pluripotent stem cells without viral vectors).
[0004] Another approach employs contacting cells to be reprogrammed with extracts of human embryonic stem cells
for reprogramming cells. This approach, however, is ethically and practically problematic.
[0005] Some other approaches use chemical factors to dedifferentiate cells (e. g. US 200710254884 A1, US
200710020759 A1), but these factors are not efficacious in fully reprogramming cells to a pluripotent state by themselves.
[0006] Thus, the technical problem underlying the present invention is to provide improved methods to reprogram
cells, in particular to dedifferentiate cells, which overcome the above-identified disadvantages, in particular allow in an
easy, efficient and safe way the provision of reprogrammed, in particular dedifferentiated cells, preferably displaying
multipotent, most preferably pluripotent, stem cell character.
[0007] The present invention solves its technical problem by the provision of a process for preparing reprogrammed
cells in vitro, comprising the process steps, preferably in the given order, a) providing cells to be reprogrammed; b)
introducing, preferably transfecting, mRNA molecules capable of reprogramming the cells into the cells provided in step
a), wherein the reprogramming mRNA molecules are coding for at least one protein selected from the group consisting
of: Ronin, Oct4, Klf4, Sox2, Nanog and TERT; and c) culturing the cells obtained in step b) in a cell culture medium and
under a condition suitable to allow translation of the introduced, preferably transfected reprogramming mRNA molecules
so as to obtain reprogrammed cells.
[0008] Thus, the present invention foresees a process which is able to prepare reprogrammed cells without the need
to permanently change the genome of the cell and without the need to use viruses to transfer transcription factors or
the like into the cell. The present invention also is advantageous in so far, as for reprogramming cells no extracts of
human embryonic stem cells or cost intensive and potentially dangerous chemical factors are needed. Thus, ethical
concerns, genetic stability problems and cancer risks are reduced or even avoided. In contrast, the present invention
provides the advantageous teaching to introduce, preferably transfect, specific mRNA molecules, in the following termed
"reprogramming mRNA molecules", into the cells, wherein these reprogramming mRNA molecules are able to reprogram
the mRNA recipient cells, preferably the cells being transfected therewith, into a dedifferentiated status. Advantageously,
the mRNA molecules introduced, preferably transfected, according to the present invention will not integrate into the
recipient’s genome and therefore do not pose a risk of cancer or genetic instability. The invention therefore foresees a
process for preparing one or more reprogrammed cells in vitro wherein said process does not include any cloning
amplification or proliferation of the mRNA recipient cells. The present invention also foresees a process for preparing
one or more reprogrammed cells in vivo, that is in a living organ, a living organism or animal, more particular a mammal.
[0009] In the context of the present invention the term "reprogramming" preferably means remodelling, in particular
erasing and/or remodelling, epigenetic marks of a cell such as DNA methylation, histon methylation or activating genes
by inducing transcription factor signal systems as for oct4. In particular, the reprogramming of the present invention
provides at least one dedifferentiated and/or rejuvenated cell, in particular provides a cell having the characteristic of a
multipotent, in particular pluripotent stem cell. Thus, in case the cell to be reprogrammed is cells which already have a
multipotent or pluripotent character, the present invention is able to maintain these cells by the reprogramming of the
present invention in their multi- or pluripotent state for a prolonged period of time. In case the cells to be reprogrammed
are in an aged or differentiated state, the present invention allows the dedifferentiation into a multipotent or pluripotent
stem cell. In a particularly preferred embodiment, multipotent cells may be reprogrammed to become pluripotent cells.
[0010] In particular, the term "reprogrammed cells" designates cells which have been changed to have a higher
differentiation and/or proliferation potential. Also, in a preferred embodiment the reprogramming of asomaticdifferentiated
cell toward a multipotent stem cell or "young" differentiated cell is termed reprogramming and the product is called a
reprogrammed cell.
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[0011] In particular, the present process allows it to enrich immature stem cells, preferably showing a high telomerase
activity, several multipotent, preferably pluripotency, markers and an increased secretion of growth factors. The present
invention provides the advantage that aged stem cells can be expanded for a longer period of time and with a higher
stem cell yield. Further, stem cell lines and tissue engineered construct drafts made or derived from cells reprogrammed
by the present process show a reduced minimal immunological risk, in particular if the patient owns cells are used as a
source for the reprogramming. Thus, the present invention provides means and methods to prepare in particular pluripo-
tent stem cells, to provide multipotent stem cells, to provide means and methods for an increased expansion of cells or
stem cells in vitro and for the rejuvenation of aged cells or aged stem cells for tissue engineering or cell therapies.
[0012] In particular, the present invention foresees, preferably in a first step, to provide cells to be reprogrammed.
Preferably, the cells to be reprogrammed may be adult, neonatal or embryonic differentiated cells, but are not limited
thereto. Preferably, the cells to be reprogrammed are adult or neonatal undifferentiated cells. All of these cells may, in
a preferred embodiment, be cell lines, immortalized cells, cells kept in cell culture, isolated cell populations, preferably
cells isolated from a donor, either a living or dead donor, or cells isolated from the environment. Cell types which can
be reprogrammed according to the present invention potentially are all cell types, and are in preferred instances fibrob-
lasts, hepatocytes, cardiac cells, cardiomyocytes, nerve cells, chondrocytes, osteoblasts, adipocytes, myoblasts, hepa-
toblasts, hepatic stem cells, insulin producing cells, neural stem cells, cardiomyogenic cells, dermatocytes, keratinocytes,
pancreatic cells, monocytes, epithelial cells or mesenchymal stem cells (MSC). Preferably, the cells may be mammalian
cells, in particular human cells or animal cells, preferably ovine, horse, ape or in particular rodent cells, preferably hamster
cells, mouse cells or rat cells. The cells may also be fish, reptile, avian, amphibian or insect cells. Preferably, the cells
to be reprogrammed are lineage-committed cells. In a further preferred embodiment the cells, in particular the cells of
the above identified origin, are stem cells, in particular post-natal stem cells or non-embryonic stem cells.
[0013] A suitable and preferred stem cell source like mesenchymal stem cells is a tissue within the human or animal
body which comprises the stem cells for use in the present invention, optionally together with other cell types. Preferably,
the suitable stem cell source is bone marrow, both adult and fetal, cytokine or chemotherapy mobilized peripheral blood,
fetal liver, umbilical cord blood, embryonic yolk sac and spleen, both adult and fetal, more preferably the stem cell source
is adult bone marrow or umbilical cord blood, most preferably the stem cell source is bone marrow. Bone marrow cells
may be obtained from any known source, including, but not limited to, ilium, sternu, tibiae, femora, spine or other bone
cavities. Preferably, the stem cells are isolated from a mammalian organism such as human, mouse or rat, and more
preferably the stem cells are isolated from a human organism.
[0014] The term "isolated cell population" is intended to mean that the cells are not in contact with other cells with
which they are usually in contact within the body of the mammal or in a tissue sample obtained directly, i.e. without
purification or enrichment step, from the mammal. A "cell population" according to the present invention may comprise
not only cells of one cell type such as fibroblasts or mesenchymal stem cells as defined for example by the expression
of a specific combination of surface markers, but also a mixture of cells of different cell types which show different
combinations of surface markers.
[0015] The cells harvested from said sources may be used directly for transfection or may be cryoconserved by freezing
them at a temperature from about - 196 °C to about - 130°C.
[0016] The cells to be reprogrammed receive, according to the present invention, in a second step at least one species
of reprogramming mRNA molecules, in particular linear and isolated mRNA molecules, selected from the group of mRNA
molecules encoding Ronin, mRNA molecules encoding Oct4, mRNA molecules encoding Klf4, mRNA molecules en-
coding Sox2, mRNA molecules encoding Nanog and mRNA molecules encoding TERT. Ronin, Oct4, Klf4, Sox2, Nanog
and TERT are proteins with the ability to reprogram cells. In the context of the present invention these proteins are
termed "reprogramming proteins" and are characterised by their ability to reprogram target cells and therefore by their
regulatory function in terms of determining the cell fate, in particular being able to dedifferentiate a target cell and/or
maintain a cell in a dedifferentiated state, preferably by being transcription factors.
[0017] Differentiation behaviour of cells and state of differentiation can be detected according to the methods set forth
below. However any method for determining the differentiation state or potency of a cell known the skilled person are
applicable as well.
[0018] In a preferred embodiment, the cell to be reprogrammed is transfected with one or more reprogramming mRNA
molecules according to the present invention. In another preferred embodiment the cell to be reprogrammed is supple-
mented with one or more reprogramming mRNA molecules according to the present invention. In another preferred
embodiment the cell to be reprogrammed is injected with one or more reprogramming mRNA molecules according to
the present invention.
[0019] The present invention thus foresees to use one or more of mRNA molecules encoding Ronin, Oct4, Klf4, Sox2,
Nanog or TERT. These mRNA molecules may, in a preferred embodiment, be molecules having the wild-type mammalian,
in particular human, animal, preferably rodent, more preferably mouse, hamster or rat or any other animal nucleotide
sequence. In a preferred embodiment of the present invention the reprogramming mRNA molecule is selected from the
group consisting of mRNA nucleotide sequence molecules being encoded by any one of the DNA sequences given
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under SEQ ID No. 1 to 16.
[0020] Of course, the invention also foresees to use mRNA molecules, whose sequence is a functional equivalent to
the polynucleotide sequence given above. In the context of the present invention a functional equivalent is a nucleotide
sequence molecule, which either codes with a different nucleotide sequence exactly the same protein as the mRNA
sequence encoded by any one of SEQ ID No. 1 to 16 or is a mRNA sequence, which encodes a protein with a different
amino acid sequence but with same or similar function, in particular being able to reprogram the cells according to the
present invention.
[0021] In a particularly preferred embodiment of the present invention the functional equivalent of the mRNA molecules
is a polynucleotide with a homologous sequence to the wild-type mRNA polynucleotide as encoded by the DNA sequence
in any one of SEQ ID No. 1 to 16. In a preferred embodiment of the present invention the degree or percentage of
homology is at least 50, 60, 70, 80, 90, 95, 99 or 100%. In a furthermore preferred embodiment a functional equivalent
of the mRNA molecules as given in any one of SEQ ID No. 1 to 16 is a mRNA sequence which is encoded by a DNA
sequence being substantially complementary to the sequences of any one of SEQ ID No. 1 to 16 or to its complementary,
preferably substantially, complementary sequence. In a furthermore preferred embodiment the functional equivalent of
the mRNA molecule as encoded by any one of the DNA sequences of SEQ ID No. 1 to 16 is a mRNA molecule being
encoded by a DNA sequence which is able to hybridize under stringent or reduced stringent conditions to any one of
the polynucleotides given in SEQ ID No. 1 to 16 or to its complementary, preferably substantially, complementary
sequence.
[0022] In the context of the present invention the term "mRNA molecule" is meant to refer to a linear polymer of
ribonucleotide molecules, which is single-stranged and serves as a template for protein synthesis.
[0023] Polynucleotides have "homologous" sequences if the sequence of nucleotides in the two sequences is the
same when aligned for maximum correspondence as described herein. Sequence comparison between two or more
polynucleotides is generally performed by comparing portions of the two sequences over a comparison window to identify
and compare local regions of sequence similarity. The comparison window is generally from about 20 to 200 contiguous
nucleotides.
[0024] The "percentage of sequence homology" for polynucleotides, herein referred to be 50, 60, 70, 80, 90, 95, 98,
99 or 100 percent sequence homology, may be determined by comparing two optimally aligned sequences over a
comparison window, wherein the portion of the polynucleotide sequence in the comparison window may include additions
or deletions (i.e. gaps) as compared to the reference sequence (which does not comprise additions or deletions) for
optimal alignment of the two sequences. The percentage is calculated by: (a) determining the number of positions at
which the identical nucleic acid base occurs in both sequences to yield the number of matched positions; (b) dividing
the number of matched positions by the total number of positions in the window of comparison; and (c) multiplying the
result by 100 to yield the percentage of sequence homology. Optimal alignment of sequences for comparison may be
conducted by computerized implementations of known algorithms, or by inspection. Readily available sequence com-
parison and multiple sequence alignment algorithms are, respectively, the Basic Local Alignment Search Tool (BLAST)
(Altschul, S.F. et al. 1990. J. Mol. Biol. 215:403; Altschul, S.F. et al. 1997. Nucleic Acid Res. 25:3389-3402) and ClustalW
programs both available on the internet. Other suitable programs include GAP, BESTFIT and FASTA in the Wisconsin
Genetics Software Package (Genetics Computer Group (GCG), Madison, WI, USA).
[0025] As used herein, "substantially complementary" means that two nucleic acid sequences in question have at
least about 65%, preferably about 70%, more preferably about 80%, even more preferably 90%, and most preferably
about 98%, sequence complementarity to each other. This means that the DNA sequence coding the functional equivalent
and the polynucleotide given in any of SEQ ID No. 1 to 16 or its complement must in a preferred embodiment exhibit
sufficient complementarity to hybridise under stringent conditions. A substantially complementary sequence is preferably
one that has sufficient sequence complementarity to the nucleotide sequence in question to result in binding.
[0026] The term "primer" as used herein refers to an oligonucleotide which is capable of annealing to the amplification
target allowing a DNA polymerase to attach thereby serving as a point of initiation of DNA synthesis when placed under
conditions in which synthesis of primer extension product which is complementary to a nucleic acid strand is induced,
i.e., in the presence of nucleotides and an agent for polymerization such as DNA polymerase and at a suitable temperature
and pH. The (amplification) primer is preferably single stranded for maximum efficiency in amplification. Preferably, the
primer is an oligodeoxy ribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products
in the presence of the agent for polymerization. The exact lengths of the primers will depend on many factors, including
temperature and source of primer.
[0027] A "pair of bi-directional primers" as used herein refers to one forward and one reverse primer as commonly
used in the art of DNA amplification such as in PCR amplification.
[0028] The terms "stringency" or "stringent hybridization conditions" refer to hybridization conditions that affect the
stability of hybrids, e.g., temperature, salt concentration, pH, formamide concentration and the like. These conditions
are empirically optimised to maximize specific binding and minimize nonspecific binding of an oligo- or polynucleotide
to its target nucleic acid sequence. The terms as used include reference to conditions under which an oligo- or polynu-
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cleotide will hybridise to its target sequence, to a detectably greater degree than other sequences (e.g. at least 2-fold
over background). Stringent conditions are sequence dependent and will be different in different circumstances. Longer
sequences hybridise specifically at higher temperatures.
[0029] Generally, stringent conditions are selected to be about 5 DEG C (degree celcius) lower than the thermal
melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined
ionic strength and pH) at which 50% of a complementary target sequence hybridises to a perfectly matched oligo- or
polynucleotide. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M Na
<+> ion, typically about 0.01 to 1.0 M Na <+> ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is
at least about 30 DEG C for short probes or primers (e.g. 10 to 50 nucleotides) and at least about 60 DEG C for long
probes or primers (e.g. greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of
destabilizing agents such as formamide.
[0030] Exemplary low stringent conditions or "conditions of reduced stringency" include hybridization with a buffer
solution of 30% formamide, 1 M NaCl, 1% SDS at 37 DEG C and a wash in 2x SSC at 40 DEG C. Exemplary high
stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37 DEG C, and a wash in 0.1x
SSC at 60 DEG C. Hybridization procedures are well known in the art and are described in e.g. Ausubel et al, Current
Protocols in Molecular Biology, John Wiley & Sons Inc., 1994.
[0031] Thus, the present invention foresees to introduce, preferably transfect, specific reprogramming mRNA mole-
cules into the cells, which mRNA molecules once introduced, preferably transfected, in the cells are able to be translated
into so called reprogramming proteins which can turn on specific genes in the cells, in particular multipotency and/or the
pluripotency genes in the cell. The mRNA molecule used according to the present invention is preferably a linear molecule
having a poly A tail, most preferably produced by in vitro transcription. Thus, in a preferred embodiment the mRNA
molecules are produced by in vitro transcription, in particular using bacterial systems. In a particular preferred embodiment
the DNA sequences of the reprogramming proteins are cloned into plasmids and amplified in bacteria, for instance E.
coli. In a further preferred embodiment, the plasmids are then isolated from the bacteria, are linearised and subjected
to restriction digestion. In a further preferred embodiment cDNA prepared by said method is transcribed into mRNA,
which in turn is incubated to destroy cDNA residues and to obtain mRNA molecules to be introduced into the cells.
[0032] Since the introduced reprogramming mRNA molecules and the proteins translated therefrom are over the time
being degraded in the cells, they cannot permanently integrate into the genome of the cell providing some of the advan-
tageous features of the present invention.
[0033] In a preferred embodiment of the present invention the present teaching foresees to introduce, preferably
transfect, the reprogramming mRNA molecules into the cell by electroporation, by lipofection, by injection, by magneto-
fection, by particle bombardment, gene gun, or by any other method known in the art suitable to introduce mRNA
molecules into a target cell.
[0034] In a particular preferred embodiment the present invention further foresees in its step c) to culture the cells into
which the reprogramming mRNA molecules have been introduced in a cell culture medium and under a condition suitable
to allow translation of the transfecting reprogramming mRNA molecules, so as to obtain the reprogrammed cells.
[0035] In a particularly preferred embodiment of the present invention the present process therefore consists of the
above-identified steps a), b) and c), preferably in this order. Accordingly, the present invention excludes any further
process steps, in particular any further substantial process step, in particular any intervening or subsequent process
steps. Thus, the present invention provides its advantages in a simple and cost-effective way.
[0036] In a particularly preferred embodiment the cell culture system is a cell culture system, comprising a cell culture
medium, preferably in a culture vessel, in particular a cell culture medium supplemented with at least one so called
"inducing substance", which is a substance suitable and determined for protecting the cells from in vitro aging and/or
inducing in an unspecific or specific reprogramming. In a particularly preferred embodiment an inducing substance
according to the present invention is a substance selected from the group consisting of reversin, resveratol, selenium,
a selenium-containing compound, EGCG ((-)-epigallocatechin-3-gallate), valporic acid and salts of valporic adic, in
particular sodium valporat.
[0037] In a particularly preferred embodiment the at least one inducing substance is present in the cell culture medium
used in step c) of the present process in a concentration from 0.001 to 100 mM, preferably from 0.005 to 50 mM.
[0038] In a particularly preferred embodiment the present invention foresees to use a concentration of reversin from
0.5 to 10 mM, preferably of 1 mM. In a furthermore preferred embodiment the present invention foresees to use resveratrol
in a concentration of 10 to 100 mM, preferably 50 mM. In a furthermore preferred embodiment the present invention
foresees to use selenium or a selenium containing compound in a concentration from 0.05 to 0.5 mM, preferably of 0.1
mM. In a furthermore preferred embodiment the present invention foresees to use EGCG in a concentration from 0.001
to 0.1 mM, preferably of 0.01 mM. In a furthermore preferred embodiment the present invention foresees to use valpouric
acid or sodium valporate in a concentration from 1 to 10 mM, in particular of 5 mM.
[0039] The present invention foresees in a furthermore preferred embodiment culturing the cells obtained in step b)
in a cell culture medium, wherein the cell culture medium comprises, optionally in combination with the inducing substance
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as specified above, at least one transient proteolysis inhibitor. The use of at least one proteolysis inhibitor in the cell
culture medium of the present invention increases the time the reprogramming proteins derived from the mRNA or any
endogenous genes will be present in the cells and thus facilitates in an even more improved way the reprogramming by
the transfected mRNA derived factors. The present invention uses in a particularly preferred embodiment as a transient
proteolysis inhibitor a protease inhibitor, a proteasome inhibitor and/or a lysosome inhibitor. In a particularly preferred
embodiment the proteosome inhibitor is selected from the group consisting of MG132, TMC-95A, TS-341 and MG262.
[0040] In a furthermore preferred embodiment the protease inhibitor is selected from the group consisting of aprotinin,
G-64 and leupeptine-hemisulfat. In a furthermore preferred embodiment the lysosomal inhibitor is ammonium chloride.
[0041] In a furthermore preferred embodiment the present invention also foresees a cell culture medium comprising
at least one transient inhibitor of mRNA degradation. The use of a transient inhibitor of mRNA degradation increases
the half-life of the reprogramming factors as well.
[0042] In a furthermore preferred embodiment of the present invention a condition suitable to allow translation of the
transfected reprogramming mRNA molecules in the cells is an oxygen content in the cell culture medium from 0.5 to 21
%, preferably from 1 to 20%, more preferably from 5 to 19% and particularly preferred from 10 to 18%. More particular,
and without wishing to be bound to theory, oxygen is used to further induce or increase Oct4 by triggering Oct4 via Hif1a.
[0043] In a preferred embodiment conditions that are suitable to support reprogramming of the cells by the mRNA
molecules in the cells are selected; more particularly, these conditions require a temperature from 30 to 38°C, preferably
from 31 to 37°C, most preferably from 32 to 36°C.
[0044] The glucose content of the medium is in a preferred embodiment of the present invention below 4.6 g/l, preferably
below 4.5 g/l, more preferably below 4 g/l, even more preferably below 3 g/l, particularly preferably below 2 g/l and most
preferably it is 1 g/l. DMEM media containing 1 g/l glucose being preferred for the present invention are commercially
available as "DMEM low glucose" from companies such as PAA, Omega Scientific, Perbio and Biosera. More particular,
and without wishing to be bound to the theory, high glucose conditions adversely support aging of cells (methylation,
epigenetics) in vitro which may render the reprogramming difficult.
[0045] In a furthermore preferred embodiment of the present invention the cell culture medium contains glucose in a
concentration from 0.1 g/l to 4.6 g/l, preferably from 0.5 g/l to 4,5 g/l and most preferably from 1 g/l to 4 g/l.
[0046] The terms "cell culture" and "culturing of cells" refer to the maintenance and propagation of cells and preferably
human, human-derived and animal cells in vitro.
[0047] "Cell culture medium" is used for the maintenance of cells in culture in vitro. For some cell types, the medium
may also be sufficient to support the proliferation of the cells in culture. A medium according to the present invention
provides nutrients such as energy sources, amino acids and anorganic ions. Additionally, it may contain a dye like phenol
red, sodium pyruvate, several vitamins, free fatty acids, antibiotics, anti-oxidants and trace elements.
[0048] For culturing the stem cells according to the present invention any standard medium such as Iscove’s Modified
Dulbecco’s Media (IMDM), alpha-MEM, Dulbecco’s Modified Eagle Media (DMEM), RPMI Media and McCoy’s Medium
is suitable before reprogramming. Ones the cells have been reprogrammed, they can in a preferred embodiment be
cultured in embryonic stem cell medium.
[0049] Preferably, the medium additionally comprises one or more additives selected from the group consisting of
vitamin D3 (1,25-dihydroxyvitamin D3, cacitriol), resveratrol (trans-3, 4’, 5-trihydroxystilbene), reversine (2-(4-mor-
pholinoanilino)- N6-cyclohexyladenine), vitamin E (RRR-α-tocopherol), valproic acid (dekapene, valproate, valrelease),
EGCG (epigallocatechin-3-gallat) and selenium. Preferably, two of the afore-mentioned additives are present, more
preferably three of the afore-mentioned additives are present, even more preferably four of the afore-mentioned additives
are present, particularly preferably five of the afore-mentioned additives are present and most preferably all of the
aforementioned additives are present.
[0050] These media are well-known to a person skilled in the art and may be purchased from companies such as
Cambrex, Invitrogen, Sigma-Aldrich or Stem Cell Technologies.
[0051] The medium may in a particular embodiment further comprise a serum component such as horse serum, human
serum or fetal calf serum (FCS). Preferably, the medium contains FCS. If present, the serum is present in a concentration
of 1 -20%, preferably of 3-18%, more preferably of 5-15%, even more preferably of 8-12% and most preferably of 10%.
Alternatively the serum component may be replaced by any of several standard serum replacement mixtures which
typically include insulin, albumin and lecithin or cholesterol.
[0052] A "culture vessel" is any vessel which is suitable for growing cells in a culture medium, in particular selected
from, but not limited to, agar, matrigel and collagen, either in fluid phase or adhered to an interior surface of the container.
Types of such specialized vessels include roller bottles, spinner flasks, petri dishes and tissue flasks. Culture vessels
are designed to be incubated in temperature, humidity and gas controlled environments to facilitate maximum cell or
tissue growth. Generally, a layer of cell culture medium or agar covers the growing surface. The portion of the vessel
not utilized as a growing surface encloses the interior gaseous environment which surrounds the cell culture. Cells,
tissues, microorganisms and the like typically are introduced into the interior of cell culture vessels through an opening
in the vessel. After introduction of the cells the opening may be closed such that the cells are not in contact with the
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environment during the culturing of the cells.
[0053] In a preferred embodiment of the present invention, the culture vessel is treated for tissue culture, which means
that the surface of the culture vessel is treated such that cells which usually grow in an adherent state grow adherently,
but cells which grow in suspension do not adhere or adhere only loosely. Such treatment may involve the irradiation of
the vessel or the coating of the vessel, for example with a special plastic, polymer or nanostructure or with proteins of
the extracellular matrix. Such vessels can comprise tissue culture dishes and tissue culture flasks and are available
from different suppliers such as Becton Dickinson, Greiner, Sigma and TPP.
[0054] The present invention also relates to a process for the production of cells exhibiting a multipotent, preferably
a multipotent, stem cell character, wherein a process according to the above is carried out.
[0055] The present invention also relates to a process for improving the expansion of stem cells in vitro, wherein a
process according to the present invention is carried out. Thus, the present invention provides the advantage of prolonging
expansion of stem cells, since the present invention keeps the cells to be expanded in a dedifferentiated status.
[0056] The present invention also relates to a process for the rejuvenation of aged cells, wherein a process according
to the present invention is carried out.
[0057] The present invention also relates to a process for inducing the dedifferentiation of cells, wherein a process
according to the present invention is carried out and wherein in particular the cells to be reprogrammed are differentiated
cells, in particular lineage-committed cells.
[0058] The present invention also relates to a process for reprogramming recipient cells of a mammal in vivo comprising
introducing reprogramming mRNA molecules into the recipient cells of the mammal wherein the reprogramming mRNA
molecules are encoding at least one reprogramming protein selected from the group consisting of Ronin, Oct4, Klf4,
Sox2, Nanog and TERT. Thus, the present invention also relates to an in vivo method for reprogramming recipient cells
of a mammal which employ the reprogramming mRNA molecules as identified above for the in vitro embodiment of the
present invention. The present invention relating to the process for reprogramming recipient cells of a mammal in vivo
thereby foresees to introduce the reprogramming mRNA molecules directly into at least one cell of a recipient mammal
that means into at least one recipient cell by suitable means such as gene gun insertion. Such a process allows the
production of a mammal in particular a human being which has at least one reprogrammed cell. Thus, this embodiment
of the present invention provides terrifically improved therapeutic application, in particular in the regenerative medicine
and/or in replacement therapy. Thus, the present invention relates to a method of treating a mammal, in particular human
being wherein reprogramming mRNA molecules are introduced into at least one cell of the recipient mammal and wherein
the reprogrammed mRNA molecules are encoded at least by encoding at least one reprogramming protein selected
from the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT.
[0059] The present invention also relates to a multipotent, in particular a pluripotent, stem cell prepared according to
any one of the methods of the present invention. Thus, the reprogrammed cells according to the present invention are
preferably multipotent, in particular pluripotent stem cells. In a preferred embodiment the cells obtained according to the
present invention are distinguished from the cells used as a starting material in step a) of the present invention by lack
of one or more markers. These cells may in a preferred embodiment be also characterized by a particular methylation
pattern, by the expression of oct4, sox2, nanog, hTERT or klf4. expression of oct4, which is not found in somatic cells
like fibroblasts, becomes expressed after transfecting mRNA (klf4, sox2 and oct4) in human fibroblasts, by improved
growth potential; and by increased differentiation potential. For pluripotency the formation of embryoid bodies, production
of cells of all three germ layers in vitro and in vivo. Examples thereof are illustrated in the accompanying figures and
example.
[0060] The reprogrammed cells obtained by the present processs may preferably be characterized by the expression
or non-expression of certain surface markers. These surface markers are usually given a cluster of differentiation (CD)
designation which describes groups of immunophenotypical surface characteristics of cells. Usually CD molecules are
membrane-bound glycoproteins which are recognized by a cluster of monoclonal antibodies that display the same cellular
reactivity. These surface molecules may for example be detected by means of a flow cytometer such as a fluorescence-
activated cell sorter (FACS) manufactured by companies such as Becton Dickinson. Methods to identify cells according
to the present invention are methods to detect cell-specific proteins, methods to detect cell-specific transcription factors
or methods to detect physiological or morphological changes. All of these methods are per se well-known in the prior
art. In particular, these methods use well-known protein or DNA or RNA detection processes and/or the reporter gene
assays. Of course, immunoassays or assays using fluorescently or radioactively labelled proteins or nucleic acids in-
cluding methods to measure enzymatic activities can be employed. Methods to detect morphological changes may
include staining methods, visually based methods or the like.
[0061] Reprogrammed cells according to the present invention may be used for therapeutic, diagnostic or scientific
purposes. In particular, these cells may be used in regenerative medicine and/or for replacement therapy.
[0062] The term "cell" not only refers to a single cell but also encompasses a cell line, a cell population or a cell clone.
[0063] The term "stem cells" refers to cells which have retained the capacity to proliferate and differentiate into one
or different cell types. Stem cells created in accordance with the present invention are preferably pluripotent stem cells,
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i.e. stem cells which have retained the capacity to differentiate into distinct cell lineages and cell types or multipotent
stem cells, retaining a more restricted differentiation potential.
[0064] It is understood that the term "stem cells" in accordance with the invention does not comprise human embryos.
Furthermore, it is understood that the term "stem cells" does not comprise pluripotent stem cells which have been directly
derived from a human embryo. Embryonic stem cells which have been derived from publicly available and previously
established stem cell lines are understood to fall within the meaning of the term "stem cells" as used by the present
invention.
[0065] A "stem cell", as used herein, refers to any self-renewing pluripotent cell or multipotent cell or progenitor cell
or precursor cell that is capable of differentiating into one or multiple cell types. Stem cells are thus cells able to differentiate
into one or more than one cell type and have preferably an unlimited growth potential. Stem cells include those that are
capable of differentiating into cells of osteoblast lineage, a mesenchymal cell lineage (e. g. bone, cartilage, adipose,
muscle, stroma, including hematopoietic supportive stroma, and tendon). "Differentiate" or "differentiation", as used
herein, refers to the process by which precursor or progenitor cells (i. e., stem cells) differentiate into specific cell types,
e. g., osteoblasts. Differentiated cells can be identified by their patterns of gene expression and cell surface protein
expression. "Dedifferentiate" or "dedifferentiation", as used herein, refers to the process by which lineage-committed
cells (e. g., myoblasts or osteoblasts) reverse their lineage commitment and become precursor or progenitor cells (i. e.,
multipotent or pluripotent stem cells). Dedifferentiated cells can for instance be identified by loss of patterns of gene
expression and cell surface protein expression associated with the lineage committed cells.
[0066] A "lineage-committed cell" as used herein, refers to any cell that has or will differentiate into a particular cell
type or related cell types. Lineage committed cells include, for example, osteoblasts, myoblasts, chrondrocytes, and
adipocytes.
[0067] Totipotent stem cells are able to create all cell types of the body, including placental cells. The earlier stage
foetal stem cells are considered totipotent, as well as the fertilised egg. They also have the ability to replicate in unlimited
numbers without losing their potential.
[0068] Pluripotent stem cells are able to create cells of all three germ layer, namely the ecto-, endo- and mesoderm.
They also have the ability to replicate in unlimited numbers without losing their potential.
[0069] Multipotent stem cells are able to produce cells of one or more germ layers or several types of tissues. They
often have an already limited self-renewal ability.
[0070] Stem cells are thus cells able to differentiate into one or more than one cell type and have preferably an unlimited
growth potential.
[0071] Progenitor cells can differentiate into one or more cell types but have a limited growth potential.
[0072] Adult stem cells are stem cells derived from an adult organism and might be multipotent or pluripotent.
[0073] Embryonic stem cells are derived from the inner mass of a blastula and are pluripotent. Embryonic stem cells
are unique because they can develop into nearly all cell types, an attribute called pluripotency. But to access these cells,
researchers must destroy a viable embryo. In this patent we are describing a way to create cells, with the characteristics
of embryonic stem cells, without the need to destroy embryos or the use of embryonic stem cells.
[0074] Induced pluripotent stem cells "IPS" cells are pluripotent stem cells artificially derived from non-pluripotent cells,
including somatic cells, adult multipotent stem cells or progenitor cells. In principal every cell containing a nuclei can be
used as source for IPS cells.
[0075] Further preferred embodiments of the present invention are the subject matter of the subclaims.
[0076] The sequence listing show the prior art DNA sequences encoding the mRNA nucleotide sequence molecules
used in the present invention:
Table 1
SEQ ID No. gene accession-number length
1 hNanog NM_024865 2098
2 mNanog NM_028016 1356
3 rNanog NM_001100781 2358
4 hSox2 NM_003106 2518
5 mSox2 NM_011443 2457
6 rSox2 NM_001109181 2323
7 hOct4 NM_002701 1411
8 mOct4 NM_013633 1346
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[0077] The designations marked "NM" and ENSMUSG refer to the NM(NCBI)- and ENSMUSG-accession numbers
as given under the publically available website http://www.ncib.nlm.nih.gov and http://www.ensembl.org.
[0078] SEQ ID No. 17 and 18 show the DNA sequence of primers used for cloning the human Nanog gene.
[0079] SEQ ID No. 19 and 20 show the DNA sequence of primers used for cloning the human Klf4 gene.
[0080] SEQ ID No. 21 and 22 show the DNA sequence of primers used for cloning the human Sox2 gene.
[0081] SEQ ID No. 23 and 24 show the DNA sequence of primers used for cloning the human Oct4 gene.
[0082] SEQ ID No. 25 and 26 show the DNA sequence of primers used for cloning the human Tert gene.
[0083] SEQ ID No. 27 and 28 show the DNA sequence of primers used for cloning the GFP gene.
[0084] The present invention will now be illustrated in more detail by way of an example and figures.
[0085] The figures show:
Figure 1: Promotor methylation of rex1, nanog and oct4 in human fibroblasts before and after reprogramming (Figure
1A: Rex; Figure 1AB: Nanog; Figure 1C: Oct4). CpG island are represented as squares. Black squares represent
methylated and white squares represent unmethylated CpG islands. All samples are primary fibroblasts from a
young male donor.
Figure 2: Fluorescence and morphology after amaxa elektroporation (klf4, sox2, oct4): Human primary fibroblasts
were transfected with 0,6 mg/ml mRNA per factor and 0,2 mg/ml GFP mRNA to visualize the transfection effciency.
Top line are fluorescence pictures and the bottom line shows the morphology of the cells after 2 days.
Figure 3: Fluorescence and morphology after Fugene transfection (klf4, sox2, oct4): Human primary fibroblasts were
transfected with 0,6 mg/ml mRNA per factor and 0,2 mg/ml GFP mRNA to visualize the transfection effciency. Top
line are fluorescence pictures and the bottom line shows the morphology of the cells after 7 days.
Figure 4: RT-PCR for Oct4: L: 20 bp Ladder (Fermentas); 1 hOct4 hypoxy factors1x transfected; 2: hOct4 hypoxy
factors 6x transfected; 3: hOct4 hypoxy factors 6x transfected +Cock; 4: hOct4 normoxy factors 1x transfected; 5:
hOct4 normoxy factors 6x transfected; 6: hOct4 normoxy factors 6x transfected +Cock; 7: hOct4 normoxy factors
6x transfected +Cock+MG-132; 1 a: hOct4 RNA after DNase digestion; 2a: hOct4 RNA after DNase digestion; 3 a:
hOct4 RNA after DNase digestion; 4a: hOct4 RNA after DNase digestion; 5a: hOct4 RNA after DNase digestion;
6a: hOct4 RNA after DNase digestion; 7a: hOct4 RNA after DNase digestion; 8: Oct4 negative control.
Figure 5: RT-PCR for hOct4: L: 20 bp Ladder (Fermentas); 1 : hOct4 hypoxy factorslx transfected (human fibroblasts);
2: hOct4 hypoxy factors 6x transfected (human fibroblasts mit mRNA transfected); 3: hOct4 hypoxy factors 6x
transfected +Cocktail (human fibroblasts transfected with mRNA and chemical reprogramming cocktail); 4: hOct
normoxy factors 1x transfected; 5: hOct4 normoxy factors 6x transfected; 6: hOct4 normoxy factors 6x transfected
+ cocktail, 7: hOct4 normoxy 6x transfected factors + cocktail + MG-132; 8: hOct4 positive control (plasmid with
hKlf4), 9: hOct4 negative control (water).
Figure 6: RT-PCR for hOct4 and GAPDH: 1 hOct4 hypoxy factorslx transfected; 2 hOct4 hypoxy factors 6x trans-
fected; 3 hOct4 hypoxy factors 6x transfected +chemical cocktail; 4 hOct4 normoxy factors 1x transfected; 5 hOct4
(continued)
SEQ ID No. gene accession-number length
9 hKlf4 NM_004235 2949
10 mKlf4 NM_010637 3057
11 rKlf4 NM_053713 2393
12 hTERT NM_198253 4018
13 mTert ENSMUSG00000021611 4237
14 rTERT NM_053423 3378
15 hRonin NM_020457 1903
16 mRonin NM_021513 1832
abbreviations: h = human; m = mouse; r = rat
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normoxy factors 6x transfected; 6 hOct4 normoxy factors 6x transfected + chemical cocktail; 7 hOct4 normoxy
factors 6x transfected + chemical cocktail + MG-132; 1 a hOct4 RNA after DNase digestion; 2a hOct4 RNA after
DNase digestion; 3a hOct4 RNA after DNase digestion; 4a hOct4 RNA after DNase digestion; 5a hOct4 RNA after
DNase digestion; 6a hOct4 RNA after DNase digestion; 7a hOct4 RNA after DNase digestion; 8a Oct4 negative
control; 1 b GAPDH hypoxy factors 1x transfected; 2b GAPDH hypoxy factors 6x transfected; 3b GAPDH hypoxy
factors 6x transfected + chemical cocktail; 4b GAPDH normoxy factors 1x transfected; 5b GAPDHnormoxy factors
6x transfected; 6b GAPDH normoxy factors 6x transfected + chemical cocktail; 7b GAPDH normoxy factors 6x
transfected + chemical cocktail + MG-132; 8b GAPDH negative control.
Figure 7: RT-PCR for hKlf4 and hNanog: L: 20 bp Ladder (Fermentas); 1a: hKlf4 hypoxy factors1x transfected
(human fibroblasts); 2a: hKlf4 hypoxy factors 6x transfected (human fibroblasts with transfected mRNA); 3 a: hKlf4
hypoxy factors 6x transfected + cocktail (human fibroblasts transfected with mRNA + chemical reprogramming
cocktail); 4a: hKlf4 normoxy factors 1x transfected; 5a: hKlf4 normoxy factors 6x transfected; 6a: hKlf4 normoxy
factors 6x transfected + cocktail, 7a: hKlf4 normoxy 6x transfected factors + cocktail + MG-132; 8a: hKlf4 pos. control
(plasmid with hKlf4), 9a: hKlf4 neg. control (water) 1b: hNanog hypoxy factorslx transfected (human fibroblasts);
2b: hNanog hypoxy factors 6x transfected (humane fibroblasts mit mRNA transfected); 3b: hNanog hypoxy factors
6x transfected + cocktail (human fibroblasts transfected with mRNA + chemical reprogramming cocktail); 4b: hNanog
normoxy factors 1x transfected; 5b: hNanog normoxy factors 6x transfected; 6b: hNanog normoxy factors 6x trans-
fected + cocktail, 7b: hNanog normoxy 6x transfected factors + cocktail + MG-132; 8b hNanog pos. control (plasmid
with hNanog), 10 hNanog neg, control (water).
Figure 8: Results from RNA BioAnalyzer Analysis (Agilent Nano Chip; Agilent Technologies) for oct4, sox2, and klf4:
[0086] Further preferred embodiments of the invention are reflected by the below consecutively numbered sentences:
1. A process for preparing reprogrammed cells in vitro, comprising
a) providing cells to be reprogrammed,
b) introducing reprogramming mRNA molecules into the cells provided in step a), wherein the reprogramming
mRNA molecules are encoding at least one reprogramming protein selected from the group consisting of Ronin,
Oct4, Klf4, Sox2, Nanog and TERT,
c) culturing the cells obtained in step b) in a cell culture medium and under a condition suitable to allow translation
of the transfected reprogramming mRNA molecules so as to obtain reprogrammed cells.
2. The process according to embodiment 1, wherein the condition suitable to allow translation is an oxygen content
in the cell culture medium from 0.5 % to 21 %.
3. The process according to embodiments 1 or 2, wherein the condition suitable to allow translation is a temperature
from 30°C to 38°C.
4. The process according to any one of the preceding embodiments, wherein the cell culture medium has a glucose
content of 0.1 g/l to 4.6 g/l.
5. The process according to any one of the preceding embodiments, wherein the cell culture medium contains at
least one inducing substance selected from the group consisting of reversin, resveratol, selenium, selenium con-
taining compounds, EGCG ((-)-epigallocatechin-3-gallate), valporic acid, salts of valporic acid and sodium valproate.
6. The process according to any one of embodiments 1 to 5, wherein the cell culture medium contains at least one
transient proteolysis inhibitor.
7. The process according to embodiment 6, wherein the transient proteolysis inhibitor is selected from the group
consisting of protease inhibitor, proteasome inhibitor and lysosome inhibitor.
8. The process according to any one of the preceding embodiments, wherein the cells to be reprogrammed are
human cells.
9. The process according to any one of the preceding embodiments, wherein the cells to be reprogrammed are non-
embryonic stem cells.
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10. A process for the production of cells exhibiting a pluripotent or multipotent stem cell character, wherein a process
according to any one of embodiments 1 to 9 is carried out.
11. A process for inducing the dedifferentiation of cells, wherein a process according to any one of embodiments 1
to 9 is carried out.
12. A process for improving the expansion of non-embryonic stem cells in vitro, wherein a process according to any
one of embodiments 1 to 9 is carried out.
13. A process for the rejuvenation of aged cells, wherein a process according to any one of embodiments 1 to 9 is
carried out.
14. A multipotent or pluripotent stem cell prepared according to any one of the methods of embodiments 1 to 10.
15. A process for reprogramming recipient cells of a mammal in vivo comprising introducing reprogramming mRNA
molecules into the recipient cells of the mammal wherein the reprogramming mRNA molecules are encoding at
least one reprogramming protein selected form the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT.
Example
1. Preparation of reprogramming mRNA
1. A) Preparation of mRNA expression plasmids
[0087] For the construction of plasmids comprising the target genes in a vector with the T7-promoter for in vitro
transcription, using PCR, digest sites before the start-codon and after the stop codon were designed for direct cloning
of the gene inserts (see Table 1) in the right direction into the pCR@II-Vector (Invitrogen).
[0088] The primers used are listed in Table 2.
[0089] A PCR for obtaining the desired digest sites was carried out with the Platinum Taq-Polymerase (Invitrogen).
Preparation of PCR-reaction on ice:
[0090]
Table 2
Name gen New digest sites for restriction enzymes Primer sequence 5’-3’ Product size
Nanog_human XbaI & Notl SEQ ID No. 17
918 bp
Nanog_human SpeI & Clal SEQ ID No. 18
Klf4_human XbaI & Notl SEQ ID No. 19
637 bp
Klf4_human HindIII & Clal SEQ ID No. 20
Sox2_human XbaI & BamHI SEQ ID No. 21
996 bp
Sox2_human HindIII & Clal SEQ ID No. 22
Oct4_human XbaI & Notl SEQ ID No. 23
1100 bp
Oct4_human BamHI & Clal SEQ ID No. 24
Tert_human XbaI & Notl SEQ ID No. 25
783 bp
Tert_human HindIII & Clal SEQ ID No. 26
GFP XbaI & Notl SEQ ID No. 27
724 bp
GFP HindIII & Clal SEQ ID No. 28
5 ml 10x PCR Buffer
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PCR-Program (Biometra Tprofessional):
[0091]
[0092] After electrophoresis in a 1 % TAE-agarose-gel, specific DNA-bands (for their size see Table 2) were cut out
and the DNA extracted and purified with the QIAquick Gel Extraction Kit (from Qiagen)
Procedure:
[0093]
- excise the DNA fragment from the agarose gel with a scalpel
- weigh the gel slice
- add 3 volumes of Buffer QG to 1 volume of gel (For example, add 300 ml of Buffer QG to each 100 mg of gel)
- incubate at 50°C for 10 min (or until the gel slice has completely dissolved)
- add 1 gel volume of isopropanol to the sample and mix
- place a QIAquick spin column in a provided 2 ml collection tube
- to bind DNA, apply the sample to the QIAquick column, and centrifuge for 1 min at 13,000 rpm
- discard flow-through
- add 0.5 ml of Buffer QG to QIAquick column and centrifuge for 1 min at 13,000 rpm
- to wash, add 0.75 ml of Buffer PE to QIAquick column and centrifuge for 1 min at 13,000 rpm
- discard the flow-through
- centrifuge the QIAquick column for an additional 1 min at 13,000 rpm
- place QIAquick column into a 1.5 ml micro centrifuge tube
- to elute DNA, add 50 ml of H20 to the centre of the QIAquick membrane, let the column stand for 1 min, and then
centrifuge for 1 min at 13,000 rpm
[0094] Digest of pCRII-Vector with the specific restriction enzymes for cloning of target-DNA
Strategy for digest of vector pCRII:
[0095]
vector pCRII digest with XbaI and SpeI for target gene human Nanog
vector pCRII digest with XbaI and HindIII for target gene human Klf4
vector pCRII digest with Xbal and BamHI for target gene human Sox2
(continued)
1 ml 10 mM dNTP mixture 0.2 mM each
1.5 ml 50 mM MgCl2
1 ml Primer mix (10 mM each) 0.2 mM each
1 ml Template DNA
0.2 ml Platinum® Taq DNA Polymerase 1.0 unit
to 50 ml DEPC-H2O
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vector pCRII digest with XbaI and BamHI for target gene human Oct4
vector pCRII digest with XbaI and HindIII for target gene human TERT
vector pCRII digest with XbaI and HindIII for target gene GFP
Preparation of digest on ice:
[0096]
- 5 ml 10x Buffer
- ≥2 mg plasmid
- 2 ml restriction enzyme
- to 50 ml DEPC-water
- incubation for 1 h at 37°C (thermo block; Eppendorf)
- heat inactivation for 20 min by the specific temperature of the enzyme
[0097] Ligation of the target-gene inserts DNA with the linear vector DNA with the T4-DNA-Ligase (Fermentas)
Preparation of the ligation on ice:
[0098]
- 50-400 ng vector DNA
- 50-400 ng insert DNA
- 2 ml 10x Buffer
- 0.2 ml (1U) T4-DNA Ligase
- to 20 ml DEPC-water
- vortex the tube and spin down in a micro centrifuge for 3-5 seconds
- incubate on room temperature for 1 h
- heat inactivation for 20 min
1. B) Transformation of the plasmids with chemical competent DH5α-bacteria
[0099]
- add 1 ml of the plasmids to 10 ml chemical competent DH5α-bacteria
- incubation for 30 min on ice
- heat shock at 42°C for 45 sec
- add 250 ml SOC-Medium to the bacteria
- incubation at 37°C for 1h with shaking
- plate out the bacteria solution on LB-kanamycin-agarose-plate and incubate the plate for 12 hours in 37°C incubator
- pick one colony of the bacteria and put the colony in 5 ml LB-medium and incubate the solution for 12 hours in a
bacteria incubator with shaking
1. C) Plasmid DNA purification with the NucleoSpin® Plasmid -KIT (Machery&Nagel)
[0100]
- 5 ml of a saturated E. coli LB culture, pellet cells in a standard bench top micro centrifuge for 30 sec at 11,000 x g.
- discard the supernatant
- for cell lysis add 250 ml Buffer A1. Re-suspend the cell pellet completely by pipetting up and down
- add 250 ml Buffer A2
- mix gently by inverting the tube 10 times and Incubate at room temperature for up to 5 min
- add 300 ml Buffer A3. Mix thoroughly by inverting the tube 10 times
- centrifuge for 5 min at 11,000 x g at room temperature
- place a NucleoSpin® Plasmid Column in a collection tube (2 ml) and load a 750 ml of the supernatant onto the column.
- centrifuge for 1 min at 11,000 x g.
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- discard flow-through and place the NucleoSpin® Plasmid Column back into the collection tube (2 ml)
- for wash the membrane with DNA: Add 600 ml Buffer A4 (supplemented with ethanol).
- centrifuge for 1 min at 11,000 x g.
- discard flow-through and place the NucleoSpin® Plasmid Column back into the collection tube (2 ml)
- dry silica membrane: centrifuge for 2 min at 1 1,000 x g and discard the collection tube (2 ml)
- elute DNA: place the NucleoSpin® Plasmid Column in a 1.5 ml micro centrifuge tube and add 50 ml H20 and incubate
for 1 min at room temperature.
- centrifuge for 1 min at 11,000 x g
- measure the DNA-concentration with the nanodrop
- DNA store at -20°C
1. D) Linearisation of the pCRII-hoct4, pCRII-hSox2, pCRII-hKlf4 plasmids for the in vitro transcription
[0101]
- pCRII-hoct4 digest with BamHI
- pCRII-hSox2 digest with HindIII
- pCRII-hKlf4 digest with HindIII
Preparation of digest on ice:
[0102]
- 5 ml 10x Buffer
- 2 mg Plasmid
- 2 ml Restriction-Enzyme
- to 50 ml DEPC-H20
- incubation for 1 h at 37°C (thermo block; Eppendorf)
- heat inactivation for 20 min by the specific temperature of the enzyme
- heat inactivate both enzyme for 20 min at 80°C
1. E) Purification of the linearized pCRII-hoct4, pCRII-hSox2, pCRII-hKlf4 plasmids with QlAquick PCR Purification Kit 
(from Qiagen)
[0103]
- add 5 volumes of Buffer PB to 1 volume of the digest sample and mix
- place a QIAquick spin column in a provided 2 ml collection tube
- to bind DNA, apply the sample to the QIAquick column and centrifuge for 60 s
- discard flow-through
- place the QIAquick column back into the same tube
- to wash, add 0.75 ml Buffer PE to the QIAquick column and centrifuge for 60 s
- discard flow-through and place the QIAquick column back in the same tube
- to dry the membrane, centrifuge the column for an additional 1 min
- place QIAquick column in a 1.5 ml micro centrifuge tube
- to elute DNA, add 10 ml H20 to the centre of the QIAquick membrane, let the column stand for 1 min, and centrifuge
the column for 1 min
- measure the DNA-concentration with the nanodrop
- store DNA at -20°C
1. F) in vitro transcription of the linearized pCRII-hoct4, pCRII-hSox2, pCRII-hKlf4 plasmids with mMessage mMachine 
high yield capped RNA Transcription Kit (from Ambion) and add a poly(A) tail to RNA transcripts (Poly(A)-Tailing Kit 
from Ambion)
Preparation of the in vitro transcription (mMESSAGE mMACHINE reaction):
[0104]
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- to 20 ml nuclease-free water
- 10 ml 2x NTP/CAP
- 2 ml 10x reaction buffer
- 1 mg linear template plasmid
- 2 ml enzyme mix
- pipette the mixture up and down gently
- short centrifugation to collect the reaction mixture at the bottom of the tube
- incubation for 2 h at 37°C
- add 1 ml TURBO DNase to the mRNA and mix well
- incubate at 37°C for 15 min
- direct after the DNase-treated reaction add the poly(A)-tail to the mRNA
Preparation for poly(A)-tail reaction:
[0105]
- 20 ml mMESSAGE mMACHlNE reaction
- 36 ml nuclease-free water
- 20 ml 5x E-PAP Buffer
- 10 ml 25 mM MnCl2
- 10 ml mM ATP
- 4 ml E-PAP
- mix gently
- incubate at 37°C for 1 h
- place reaction on ice
- lithium chloride precipitation of the mRNA with poly(A)-tail:
- add 30 ml LiCl Preciptitation Solution
- mix thoroughly
- chill for 30 min at -20°C
- centrifuge at 4°C for 15 min at maximum speed to pellet the RNA
- remove the supernatant
- wash the pellet once with 1 ml 70% ethanol
- centrifuge at 4°C for 15 min at maximum speed to pellet the RNA
- remove the 70% ethanol
- air-dry the pellet
- solve the RNA-Pellet with 30-50 ml nuclease-free-water
- the concentration of the RNA is measured with the nanodrop
- the quality of the RNA is measured with the Agilent nano-chip
2. Preparation of target cells
2. A) Preparation of mouse and rat MSCs
[0106]
- kill the rat or mouse with CO2-gassing
- spray the rats and mice with 70% Ethanol to kill of bacteria and fungal spores
- remove the coat from the skin
- remove the back legs cleanly at the hip joint
- under sterile conditions, remove all soft tissue and separate the bones
- remove the growth plates both femur and tibia
- insert holes with a needle into the bones on both ends
- place the bones in eppendorf tubes (for mice) or in falkon tubes (for rats) and spin at 2000 rpm for 1 min (all of the
bone marrow will be deposited in the bottom of the tube sitting in spacers); remove the bones and spacer
- re-suspend the marrow in 0,5 ml medium (DMEM low glucose; 10 % FCS; 1 % Pen/Strep)
- disseminate the marrow of one leg from a rat in 1 T-75 flask with 12 ml medium
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- disseminate the marrow of two legs from a mouse in 1 10 cm petri-dish with 12 ml medium
2. B) Preparation of human MSC
[0107]
- get a bone marrow aspirate
- re-suspend in DMEM (low glucose, 10%FCS)
- plate out in a tissue culture flask
- growth for 5 days and then change media
- thereafter change the medium twice weekly
- culture in tissue culture flask until 80% confluency and subcul ture until needed
2. C) Preparation of mouse and rat fibroblasts
[0108]
- cut of the tail
- shave the tail with a scalpel
- spray the tail with 70% ethanol to kill of bacteria and fungal spores
- remove the skin from the tail
- place the skin in a 10 cm petri dish
- under sterile conditions, cut the skin in small pieces (5 x 5 mm)
- digest the skin-pieces with 0,05 % Trypsin EDTA for 20 min in 37°C CO2-Incubator
- wash the trypsin from the skin-dishes with medium (DMEM high glucose, 10 % FCS, 1 % Pen/Strep), remove the
medium and wash again for 3-4 times
- then incubate the skin pieces in 37°C CO2-Incubator and change the medium every day, after 1 week the fibroblasts
growth out
2. D) Preparation of human fibroblasts
[0109]
- place prepuce in petri dish
- wash two times with PBS
- remove fat
- wash with PBS one time
- cut the skin in small pieces (2 mm)
- add 10ml) dispase (2 U/ml)
- incubate at 4°C for 16-18 h
- discard dispase solution
- add 5 ml PBS
- seperate dermis and epidermis
- transfer dermis to new dish and add 10ml collagenease (500 U/ml)
- make very small pieces
- transfer pieces into a 50 ml falcon tube with solution and incubate for 45 min (37°C; 5% CO2)
- centrifuge at 1000rpm for 5 min
- discard supernatant and resuspend pellet in DMEM (10% FCS)
- centrifuge again
- reuspend pellet in 2 ml DMEM (10% FCS) and transfer into a T75 cell culture flacon
- expanded cells until use
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3. mRNA Transfection
3. A) mRNA-transfection of human fibroblasts, human MSC, rat fibroblasts, rat MSC, mouse fibroblasts and mouse MSC 
with AMAXA, FugeneHD, Lipofectamine™ LTX Reagent and PLUS™ Reagent
1) AMAXA-Transfection with the Human Dermal Fibroblast Nucleofector® Kit (6 well-plate):
Preparation for one electroporation in certified Amaxa cuvette:
[0110]
- mRNA of oct4, sox2 and klf4 in sum of 2 mg
- 4x105 cells
- 100 ml Nucleofector® Solution
- choose the program U-023 by the Amaxa-electroporation-machine
- re-suspend the cells in the cuvette with 500 ml fibroblast or MSC-Medium
- provide 5 ml fibroblast or MSC-Medium with or without Cocktail in every well of a 6 well-plate
- plate out 100.000 cells in each well of a 6 well-plate
Cocktail composition:
[0111]
- Resveratrol 0,05 mM
- Selenium 0,1 mM
- EGCG ((-)-Epigallocatechin gallate) 0,01 mM
- TSA (Trichostatin A) 0,015 mM
- Reversin 1 mM
- VPA (2-Propylpentanoic acid free acid) 6 mM
- 5’Aza (5-Aza-2’-deoxycytidine) 1 mM
- at day 1: the cocktail is with 5’Aza and without TSA; after 48 hours 5’Aza replaced by TSA
- every 72 hours new transfection with FuGENE® HD Transfection Reagent (Roche)
2) Transfection FuGENE® HD Transfection Reagent (Roche)
[0112] >
- before transfection: change to antibiotic free medium
Transfection procedure
[0113]
- Dilute mRNA with serum-free and antibiotic-free medium to a concentration of 2 mg mRNA at a volume of 100 ml
for each well (6well-plate)
- Pipet the 8 ml FuGENE® HD Transfection Reagent (Ratio: 8:2 Transfection reagent to mRNA) directly into the
medium pipette up and down
- Incubate the transfection reagent: mRNA complex for 15 minutes at room temperature
- Add the transfection complex to the cells in a drop-wise manner
- Swirl the wells to ensure distribution over the entire plate surface
- after 4-6 hours change to medium (contains 10 % FCS, 1 % Pen/Strep) with or without cocktail
- one transfected 6 well plate incubate at 21 % O2-condition (normoxy) and a second plate incubate at 1 % 02-
condition (hypoxy) at 37°C incubator
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3) Alternative transfection with Lipofectamine™ LTX Reagent or PLUS™ Reagent (Invitrogen)
a) Transfection FuGENE® HD Transfection Reagent (Roche)
[0114]
- plate out 7000 cells in 500 ml medium per well of a 24 well-plate
- incubate over night
- for transfection: change to antibiotic free medium
- lute 0,5 mg mRNA in 25 ml serum-free and antibiotic-free medium for each well (24well-plate)
- pipette the FuGENE® HD Transfection Reagent 2 ml (Ratio: 8:2 Transfection reagent to mRNA) directly into the
medium
- pipette up and down
- incubate the transfection reagent: mRNA complex for 15 minutes at room temperature
- add the transfection complex to the cells in a drop-wise manner
- swirl the wells to ensure distribution over the entire plate surface
- after 4-6 hours change to medium (contains 10 % FCS, 1 % Pen/Strep) with or without cocktail
b) Lipofectamine™ LTX Reagent and PLUS™ Reagent (Invitrogen)
[0115]
- plate out 7000 cells in 500 ml Medium per well of a 24 well-plate
- incubation over night
- before transfection: change to antibiotic free medium
- dilute 0,5 mg mRNA in 100 ml serum-free and antibiotic-free medium for each well (24well-plate)
- mix gently
- mix PLUS Reagent gently before use
- add 0,5 ml PLUS™ Reagent in the mRNA-Medium mix, mix gently and incubate 5 min at room temperature mix
Lipofectamine™ LTX Reagent gently before use
- add 1,25 ml directly to the diluted mRNA); mix gently
- incubate for 30 min at room temperature
- add the 100 ml mRNA- Lipofectamine™ LTX Reagent complex
- to the well
- mix gently by rocking the plate back and forth
- incubate the cells at 37°C in the CO2 incubator for 4-6 hours
- change to medium with or without cocktail
- during the optimization of the transfection efficiency → in crease of the amount of mRNA concentration at 1 mg per
well (24 well plate)
- every 72 h repeat the transfection with FuGENE® HD or Lipofectamine™ LTX Reagent and PLUS™ Reagent
4. Protease inhibitor treatment (MG132) to increase the half-life of the proteins produced by the transfected mRNA:
[0116]
- 48h after transfection: treatment of two wells in every plate with MG-132 (10 mM/well) with and without cocktail for
6 h, than change medium
5. Results
[0117] Analysis of mRNA amount (per PCR) of the transfected or internal genes (oct4, nanog, hTERT, sox2, klf4) and
promoter analysation (of nanog, sox, oct4)
[0118] The reprogramming results are set forht in figures 1 to 8
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6. Tools and Methods
6.1 RNA-Isolation with TriFaSt™(Peglab)
[0119]
- 1 ml Trifast per 10 cm2 of the culture dish area
- samples can be stored for a long time at -80°C or be directly used
- samples should be kept for 5 minutes at room temperature
- addition of 0.2 ml of chloroform
- shake samples by hand vigorously for 15 seconds
- incubation for 3 minutes at room temperature
- centrifugation at 12.000 x g
- transfer the aqueous phase with RNA to new tube (save the interphase and organic phase at 4°C for the isolation
of DNA and proteins).
- precipitation of the RNA with 0.5 ml of Isopropanol per 1 ml of Tri-Fast™ used for the initial homogenization.
- incubation on ice for 15 min
- centrifuge for 10 minutes at 4°C at 12.000 g
- remove the supernatant
- wash the RNA pellet twice with 75% ethanol by vortexing
- subsequent centrifugation for 8 minutes at 7,500 x g (4°C)
- remove the excess isopropanol from the RNA pellet by airdrying
- re-suspend the RNA pellet in Rnase-free water (DEPC-H20) → 30 ml - 50 ml
- dissolve the RNA pellet by passing the solution through a pipette tip several times
- incubating the solution for 10 min at 55°C
- pipetting it up and down.
- Heating the sample at 55-60°C might help to dissolve the pellet
- measure the RNA-Concentration → NanoDrop
- samples store at -80°C for 2-3 months
6.2 DNA-Isolation:
[0120]
- Remove any left aqueous phase after RNA removal
- precipitate the DNA with 0.3 ml of 100% ethanol per ml Tri-Fast™
- mix well by inversion
- store the samples at room temperature for 2-3- minutes
- centrifugation at 2,000 x g at 4°C for 5 minutes
- move the DNA supernatant (store it at 4°C for the protein isolation)
- DNA pellet washed twice with 1 ml 0.1 M sodium citrate in 10% ethanol
- At each wash step keep the DNA in 0.1 M sodium citrate /10% ethanol for 30 minutes at room temperature (with
periodic mixing)
- centrifuge at 4°C for 5 minutes at 2,000 x g
- after these two washes suspend the DNA pellet in 2 ml of 75% ethanol
- keep it at room temperature with periodic mixing for 15 minutes
- centrifuge at 2,000 x g for 5 minutes at 4°C
- dry the DNA pellet briefly for 5-10 minutes under vacuum and
- dissolve it in 8 mM NaOH by slowly passing the pellet through a wide bore pipet.
- Try to adjust the final concentration of DNA to 0.2-0.3 mg/ml with 8 mM NaOH
6.3 RNA treatment with DNase I (Fermentas):
[0121]
- 1 mg RNA
- 1 ml 10X reaction buffer with MgCI2
- 1 ml (1 u) DNase
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- to 9 ml DEPC-H2O
- incubate at 37°C for 30 minutes
- inactivation of DNase I: Add 1 ml 25mM EDTA and incubate at 65°C for 10 min
6.4 RT-PCR with SuperScript™ III Reverse Transcriptase (Invitrogen)
Reaction condition:
[0122]
- 1 mI oligo(dT)20 Primer
- 1 mg RNA
- 1 ml 10 mM dNTP Mix (10 mM each dATP, dGTP. dCTP and dTTP)
- to 13 ml DEPC-H20
- heat mixture to 65°C for 5 minutes
- incubate on ice for 1 min
Add:
[0123]
- 4 ml 5X First-Strand Buffer
- 1 ml 0.1M DTT
- 1 ml SuperScript™ III RT (200 units/ml)
- mix by pipetting gently up and down
- incubate at 50°C for 60 min
- inactivate the reaction by heating at 70°C for 15 minutes
- store the cDNA at -20°C
6.5 PCR of human oct4 (control the human fibroblasts):
[0124] Primersequence: hoct4_S: gaggatcaccctgggatatacahoct4_as: agatggtcgtttggctgaatac
[0125] Product size: 100 bp
6.6 PCR with Patinum Taq-Poymerase (Invitrogen)
Preparation of PCR-reaction on ice:
[0126]
- 5 ml 10X PCR Buffer
- 1 ml 10 mM dNTP mixture 0.2 mM each
- 1.5 ml 50 mM MgCI2
- 1 ml Primer mix (10 mM each) 0.2 mM each
- 1 ml Template DNA
- 0,2 ml Platinum® Taq DNA Polymerase 1.0 unit
- to 50 ml DEPC-H20
PCR-Program (Biometra Tprofessional):
[0127]
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PCR-control with 3% TAE-agarose-gel for electrophoresis
6.7 Protocol to produce iPScells
6.7.1 BD Matrigel™ hESC-qualified Matrix
[0128]
- put the sterilized tip box and eppendorf tubes over night in - 20°C freezer
- thaw the Matrigel bottle on ice in the 4°C fridge overnight
- aliquot Matrigel for hESC upon arrival, store at -80°C, only thaw once and do not re-freeze to avoid breakdown of
growth factors
- for coating purposes, dilute Matrigel appropriately by using serum-free medium (0.3 mg/ml for iPS, 1 mg/ml for hESC)
- add 50 ml Matrigel-dilution per cm2 growth surface
- incubate 60 min at RT under sterile conditions or overnight at 4°C
- soak off remaining Matrigel/medium
- Medium: mTeSRI (Stem Cell Technology)
[0129] Notes: Coating recommendations (0.3 mg/ml) is of course dependant on the cell type that you are using to
generate iPS. It is recommended to coat (not gel!) plastics for hESC culture using 1 ug Matrigel/ml. Use plates immediately
or store for max 7 days at 4°C covered with serum-free medium under aseptical conditions (sealed).
[0130] Please note that you always should process, store and use your coated Matrigel plates exactly the same way
to avoid variabilities (mainly through breakdown of growth factors). In the beginning or for establishment it nessesary to
titrate a coating volume and - concentration (maybe 3 dilutions 0.3, 0.6, 1 ug/ul) that suit your specific type of cells best.
6.7.2 BD Matrigel™ Basement Membrane Matrix, Growth Factor Reduced (GFR)
[0131]
- aliquote the matrigel such as hESC-qualified Matrigel
- thaw tube overnight on ice at 4°C
- dilute with 6 ml cold basal media and mix well
- add 1 ml per well of 6 well plate
- incubate the plate at room temperature for one hour or overnight at 4°C
- plate may either be used immediately or stored at 4°C (plate are be good for least one week)
- remove the excess liquid and wash once with basal medium
- basal medium component: D-MEM/F-12; 20% KO Serum Replacer; 1% Non-essential Amino Acids; 1mM L-
Glutamine, 0.1 mM 2-Mercaptoethanol; 100 ng/ml bFGF
- use mouse cells then add LIF-supernatent to the basal medium
6.7.3 Production of LIF-supernatant
[0132]
- coat petri dish (145 mm) with 0,1 % gelantine (Bovine Type x?, Sigma)
- plate 3x10e10 LIF producing feeder cells SNL in every dish
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- Medium component: D-MEM high glucose, 10% FCS, 1 % Pen/Strep; 1 % L-Glutamine
- after 24 hours collect the medium from the dish and filter through a 0,22 mm filter
- aliquote the medium containing LIF in 500 ml aliquots and store at -20°C
- change media after 24 hours or 48 hours
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Claims
1. A process for preparing reprogrammed mammalian cells in vitro without the use of a virus, comprising
a) providing isolated mammalian cells to be reprogrammed,
b) transfecting one or more reprogramming mRNA molecules into the cells provided in step a), wherein the
reprogramming mRNA molecules are encoding at least one reprogramming protein selected from the group
consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT,
c) culturing the cells obtained in step b) in a cell culture medium and under a condition suitable to allow translation
of the transfected reprogramming mRNA molecules, and wherein a condition suitable to allow translation of the
transfected reprogramming mRNA molecules is a temperature from 30°C to 38°C and is an oxygen content in
the cell culture medium from 0.5% to 21% and wherein the cell culture medium has a glucose content of 0.1 g/l
to 4.6 g/l, so as to obtain reprogrammed cells, wherein said reprogrammed cells are mammalian cells exhibiting
a pluripotent or multipotent stem cell character.
2. The process according to any one of the preceding claims, wherein the cell culture medium contains at least one
inducing substance selected from the group consisting of reversine, resveratrol, selenium, selenium containing
compounds, EGCG (epigallocatechin-3-gallate), valproic acid, salts of valproic acid and sodium valproate.
3. The process according to any one of the preceding claims, wherein the cell culture medium contains at least one
transient proteolysis inhibitor.
4. The process according to claim 3, wherein the transient proteolysis inhibitor is selected from the group consisting
of protease inhibitor, proteasome inhibitor and lysosome inhibitor.
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5. The process according to any one of the preceding claims, wherein the cells to be reprogrammed are human cells.
6. A process for inducing the dedifferentiation of mammalian cells, wherein a process according to any one of claims
1 to 6 is carried out.
7. A process for improving the expansion of mammalian stem cells in vitro, wherein a process according to any one
of claims 1 to 6 is carried out, comprising
a) providing isolated mammalian cells to be reprogrammed,
b) transfecting one or more reprogramming mRNA molecules into the cells provided in step a), wherein the
reprogramming mRNA molecules are encoding at least one reprogramming protein selected from the group
consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT,
c) culturing the cells obtained in step b) in a cell culture medium and under a condition suitable to allow translation
of the transfected reprogramming mRNA molecules, and wherein a condition suitable to allow translation of the
transfected reprogramming mRNA molecules is a temperature from 30°C to 38°C and is an oxygen content in
the cell culture medium from 0.5% to 21% and wherein the cell culture medium has a glucose content of 0.1 g/l
to 4.6 g/l, so as to obtain reprogrammed cells, wherein said reprogrammed cells are mammalian cells exhibiting
a pluripotent or multipotent stem cell character,
wherein said culturing in step c) is characterized by prolonging expansion of the pluripotent or multipotent stem
cells obtained, whereby said stem cells to be expanded are kept in a dedifferentiated status.
8. A process for the rejuvenation of aged mammalian cells, wherein a process according to any one of claims 1 to 6
is carried out.
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